CIK: 0001056807
Total reported value
$3.1B
Reporting period: 2026-03-31 · Number of holdings: 41
BVF INC/IL disclosed 41 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $3.1B and a quarterly turnover rate of 29.5%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "B"
Bvf Inc/il's disclosed holdings carry a Herfindahl concentration index of 0.058 — mathematically equivalent to about 17 equally-sized positions, well below its 41 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 1.20), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 11% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add NKTR
+64.1% $118.2M
Trim GPCR
-0.6% -$75.2M
Trim OLMA
0.0% -$53.4M
Trim XNCR
0.0% -$23.2M
Add IRON
+95.7% $29.7M
Trim KURA
-2.0% -$20.9M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics INC | Stock-Other | 14.60% | +0.19% | — | |
| 2 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 9.50% | +0.74% | -18.99% | |
| 3 | RVMD | Revolution Medicines INC | Stock-Healthcare | 8.85% | -0.15% | -14.90% | |
| 4 | NKTR | Nektar Therapeutics | Stock-Other | 5.87% | +3.65% | +64.12% | |
| 5 | GPCR | Structure Therapeutics INC | Stock-Other | 5.31% | -2.84% | -0.57% | |
| 6 | MIRM | Mirum Pharmaceuticals INC | Stock-Other | 4.66% | +0.68% | +5.98% | |
| 7 | GHRS | GH Research PLC | Stock-Other | 3.87% | +0.10% | -2.01% | |
| 8 | PVLA | Palvella Therapeutics INC | Stock-Other | 3.82% | +0.72% | +9.33% | |
| 9 | ZYME | Zymeworks INC | Stock-Other | 2.98% | -0.51% | -5.19% | |
| 10 | XNCR | Xencor INC | Stock-Other | 2.74% | -0.94% | — | |
| 11 | STOK | Stoke Therapeutics INC | Stock-Other | 2.64% | +0.22% | +12.44% | |
| 12 | CGEM | Cullinan Therapeutics INC | Stock-Other | 2.60% | +0.60% | — | |
| 13 | IRON | Disc Medicine INC | Stock-Other | 2.59% | +0.85% | +95.74% | |
| 14 | XOMA | Xoma Royalty Corporation | Stock-Other | 2.59% | +0.27% | — | |
| 15 | OLMA | Olema Pharmaceuticals INC | Stock-Other | 2.52% | -1.94% | — | |
| 16 | TYRA | Tyra Biosciences INC | Stock-Other | 2.41% | +0.53% | -7.12% | |
| 17 | GLUE | Monte Rosa Therapeutics INC | Stock-Other | 2.34% | +0.32% | +16.29% | |
| 18 | ALKS | Alkermes plc | Stock-Healthcare | 2.25% | +2.25% | NEW | |
| 19 | KURA | Kura Oncology INC | Stock-Other | 2.19% | -0.82% | -1.99% | |
| 20 | ACIU | AC Immune SA | Stock-Other | 1.74% | -0.36% | — | |
| 21 | ✓ | Crescent Biopharma INC. | Stock-Other | 1.61% | +0.51% | — | |
| 22 | ANNX | Annexon INC | Stock-Other | 1.54% | — | -4.71% | |
| 23 | CMPX | Compass Therapeutics INC | Stock-Other | 1.31% | -0.09% | — | |
| 24 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.24% | -0.45% | -13.06% | |
| 25 | SEPN | Septerna INC | Stock-Other | 1.04% | -0.57% | -21.36% | |
| 26 | STRO | Sutro Biopharma INC | Stock-Other | 0.99% | +0.99% | NEW | |
| 27 | FHTX | Foghorn Therapeutics INC | Stock-Other | 0.89% | -0.07% | +10.18% | |
| 28 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.85% | -0.32% | -37.80% | |
| 29 | IVVD | Invivyd INC | Stock-Other | 0.81% | -0.81% | — | |
| 30 | AVTX | Avalo Therapeutics INC | Stock-Other | 0.78% | -0.05% | +20.48% | |
| 31 | ELDN | Eledon Pharmaceuticals INC | Stock-Other | 0.62% | +0.30% | — | |
| 32 | AVR | Anteris Technologies Global | Stock-Other | 0.53% | +0.53% | NEW | |
| 33 | XFOR | X4 Pharmaceuticals INC | Stock-Other | 0.29% | -0.01% | — | |
| 34 | VTLUSD | Immunic INC | Stock-Other | 0.27% | +0.13% | — | |
| 35 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.26% | +0.26% | NEW | |
| 36 | TCRX | Tscan Therapeutics INC | Stock-Other | 0.18% | — | +6.47% | |
| 37 | IMA | Imagenebio INC | Stock-Other | 0.18% | -0.01% | +38.39% | |
| 38 | TENX | Tenax Therapeutics INC | Stock-Other | 0.17% | +0.03% | — | |
| 39 | MOLN | Molecular Partners AG -adr | Stock-Other | 0.17% | -0.03% | — | |
| 40 | IVA | Inventiva SA - Adr | Stock-Other | 0.12% | +0.01% | — | |
| 41 | ✓ | Engene Holdings INC | Stock-Other | 0.08% | — | — |
Performance for Q3 2026
+24.6%
Performance Last 4 Quarters
+164.4%
Based on 69% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 41 | $3.1B | 29 | |
| 2025-12-31 | 41 | $3.0B | 55 | |
| 2025-09-30 | 46 | $2.5B | 78 | |
| 2025-06-30 | 44 | $2.8B | 0 | |
| 2025-03-31 | 51 | $2.5B | 100 | |
| 2024-12-31 | 53 | $3.0B | 0 | |
| 2024-09-30 | 55 | $3.4B | 0 | |
| 2024-06-30 | 60 | $3.6B | 0 | |
| 2024-03-31 | 62 | $3.6B | 0 | |
| 2023-12-31 | 70 | $4.0B | 0 | |
| 2023-09-30 | 69 | $3.7B | 0 | |
| 2023-06-30 | 67 | $3.6B | 0 | |
| 2023-03-31 | 72 | $2.7B | 0 | |
| 2022-12-31 | 78 | $2.4B | 0 | |
| 2022-09-30 | 80 | $2.4B | 0 | |
| 2022-06-30 | 79 | $2.1B | 0 | |
| 2022-03-31 | 81 | $2.5B | 0 | |
| 2021-12-31 | 83 | $2.8B | 0 | |
| 2021-09-30 | 75 | $2.6B | 0 | |
| 2021-06-30 | 70 | $2.7B | 54 | |
| 2021-03-31 | 67 | $2.7B | 55 | |
| 2020-12-31 | 68 | $2.5B | 69 | |
| 2020-09-30 | 62 | $1.8B | 54 | |
| 2020-06-30 | 57 | $1.6B | 62 | |
| 2020-03-31 | 57 | $1.1B | 49 | |
| 2019-12-31 | 57 | $1.3B | 71 | |
| 2019-09-30 | 59 | $951.8M | 55 | |
| 2019-06-30 | 56 | $915.6M | 39 | |
| 2019-03-31 | 53 | $893.1M | 41 | |
| 2018-12-31 | 55 | $765.2M | 46 | |
| 2018-09-30 | 57 | $1.1B | 31 | |
| 2018-06-30 | 51 | $1.0B | 48 | |
| 2018-03-31 | 43 | $986.5M | 58 | |
| 2017-12-31 | 43 | $829.5M | 55 | |
| 2017-09-30 | 37 | $786.7M | 52 | |
| 2017-06-30 | 34 | $644.0M | 42 | |
| 2017-03-31 | 30 | $587.9M | 54 | |
| 2016-12-31 | 29 | $497.7M | 39 | |
| 2016-09-30 | 29 | $530.7M | 50 | |
| 2016-06-30 | 34 | $469.4M | 59 | |
| 2016-03-31 | 32 | $404.1M | 47 | |
| 2015-12-31 | 30 | $586.8M | 39 | |
| 2015-09-30 | 27 | $495.0M | 40 | |
| 2015-06-30 | 30 | $566.6M | 43 | |
| 2015-03-31 | 30 | $478.2M | 37 | |
| 2014-12-31 | 31 | $514.1M | 52 | |
| 2014-09-30 | 32 | $481.6M | 60 | |
| 2014-06-30 | 29 | $632.3M | 34 | |
| 2014-03-31 | 28 | $645.1M | 31 | |
| 2013-12-31 | 26 | $571.6M | 32 | |
| 2013-09-30 | 26 | $581.2M | 39 | |
| 2013-06-30 | 24 | $515.3M | 0 |
Bvf Inc/il's most significant position changes for 2026-03-31: New buy: Alkermes plc (ALKS); Sold out: Abivax Sa-adr (ABVX); New buy: Sutro Biopharma INC (STRO); Sold out: Repare Therapeutics INC (RPTX); New buy: Anteris Technologies Global (AVR).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NKTR | Nektar Therapeutics | +3.7% | +64.12% | Add |
| 2 | IRON | Disc Medicine INC | +0.9% | +95.74% | Add |
| 3 | MLTX | Moonlake Immunotherapeutics | +0.7% | -18.99% | Trim |
| 4 | PVLA | Palvella Therapeutics INC | +0.7% | +9.33% | Add |
| 5 | MIRM | Mirum Pharmaceuticals INC | +0.7% | +5.98% | Add |
| 6 | CGEM | Cullinan Therapeutics INC | +0.6% | — | Unchanged |
| 7 | TYRA | Tyra Biosciences INC | +0.5% | -7.12% | Trim |
| 8 | ✓ | Crescent Biopharma INC. | +0.5% | — | Unchanged |
| 9 | GLUE | Monte Rosa Therapeutics INC | +0.3% | +16.29% | Add |
| 10 | ELDN | Eledon Pharmaceuticals INC | +0.3% | — | Unchanged |
| 11 | XOMA | Xoma Royalty Corporation | +0.3% | — | Unchanged |
| 12 | STOK | Stoke Therapeutics INC | +0.2% | +12.44% | Add |
| 13 | KYMR | Kymera Therapeutics INC | +0.2% | — | Unchanged |
| 14 | VTLUSD | Immunic INC | +0.1% | — | Unchanged |
| 15 | GHRS | GH Research PLC | +0.1% | -2.01% | Trim |
| 16 | TENX | Tenax Therapeutics INC | 0% | — | Unchanged |
| 17 | IVA | Inventiva SA - Adr | 0% | — | Unchanged |
| 18 | ANNX | Annexon INC | — | -4.71% | Trim |
| 19 | TCRX | Tscan Therapeutics INC | — | +6.47% | Add |
| 20 | ✓ | Engene Holdings INC | — | — | Unchanged |
| 21 | XFOR | X4 Pharmaceuticals INC | 0% | — | Unchanged |
| 22 | IMA | Imagenebio INC | 0% | +38.39% | Add |
| 23 | MOLN | Molecular Partners AG -adr | 0% | — | Unchanged |
| 24 | AVTX | Avalo Therapeutics INC | -0.1% | +20.48% | Add |
| 25 | FHTX | Foghorn Therapeutics INC | -0.1% | +10.18% | Add |
| 26 | CMPX | Compass Therapeutics INC | -0.1% | — | Unchanged |
| 27 | RVMD | Revolution Medicines INC | -0.2% | -14.90% | Trim |
| 28 | FDMT | 4d Molecular Therapeutics In | -0.3% | -37.80% | Trim |
| 29 | ACIU | AC Immune SA | -0.4% | — | Unchanged |
| 30 | IMCR | Immunocore Holdings Plc-adr | -0.5% | -13.06% | Trim |
| 31 | ZYME | Zymeworks INC | -0.5% | -5.19% | Trim |
| 32 | SEPN | Septerna INC | -0.6% | -21.36% | Trim |
| 33 | IVVD | Invivyd INC | -0.8% | — | Unchanged |
| 34 | KURA | Kura Oncology INC | -0.8% | -1.99% | Trim |
| 35 | XNCR | Xencor INC | -0.9% | — | Unchanged |
| 36 | OLMA | Olema Pharmaceuticals INC | -1.9% | — | Unchanged |
| 37 | GPCR | Structure Therapeutics INC | -2.8% | -0.57% | Trim |
| 38 | ALKS | Alkermes plc | — | NEW | New buy |
| 39 | ABVX | Abivax Sa-adr | — | EXIT | Sold out |
| 40 | STRO | Sutro Biopharma INC | — | NEW | New buy |
| 41 | RPTX | Repare Therapeutics INC | — | EXIT | Sold out |
| 42 | AVR | Anteris Technologies Global | — | NEW | New buy |
| 43 | PEPG | Pepgen INC | — | EXIT | Sold out |
| 44 | AXSM | Axsome Therapeutics INC | — | EXIT | Sold out |
| 45 | OKUR | Onkure Therapeutics Inc-a | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-12 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-13 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-14 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-15 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-14 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-07 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-14 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-15 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-16 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-16 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-11-16 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-08-14 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-05-15 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-02-17 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-05-15 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-02-14 | 13F-HR | View on EDGAR |
| 2013-09-30 | 2013-11-14 | 13F-HR | View on EDGAR |
| 2013-06-30 | 2013-08-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001666736
Total reported value
$3.1B
350 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001484150
Total reported value
$3.1B
27 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001502976
Total reported value
$3.1B
930 stks
2020-06-30
Stale — no recent filing
AUM within 0.2% of this institution
Institutions with overlapping top holdings
CIK 0002018299
Total reported value
$761.7M
54 stks
2026-03-31
2 of the top 5 holdings overlap, including Revolution Medicines INC
CIK 0000310158
Total reported value
$349.4M
14 stks
2026-03-31
1 of the top 5 holdings overlap, including Kymera Therapeutics INC
CIK 0000909661
Total reported value
$17.5B
172 stks
2026-03-31
1 of the top 5 holdings overlap, including Revolution Medicines INC